4Kiyanagi T, Miyazaki T, Kume A, et al. Decrease in CETP activity by fenofibrate may increase LDL particle size measured by HPLC method in patients with coronary artery disease [J]. Atherosclerosis, 2006, 7 (3 Suppl):559. 被引量：1
5Rizzo M, Berneis K. The clinical significance of the size of love density-lipoproteins and the modulation of subclasses by fibrates [J]. Curr Med Res Opin, 2007, 23 (5) :1103-1111. 被引量：1
6Superko RH, Berneis KK, Williams P, et al. Gemfibrozil re- duces small low-density lipoprotein more in normolipemic sub- jects classified as low density lipoprotein pattern B compared with pattern A[J]. Am J Cardiol, 2005, 96 (9): 1266-1272. 被引量：1
7Rizzo M, Rini GB,Berneis K. Effects of statins, fibrates, rosu- vastatln and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients [J]. Adv Ther, 2007, 24 (3): 575-582. 被引量：1
8van Bilsen M, van Nieuwenhoven FA. PPARs as therapeutic targets in cardiovascular disease [J]. Expert Opin Ther Tar- gets, 2010, 14 (10): 1029-1045. 被引量：1
9Undas A, Celifliska-Lowenhoff M. Antiplatelet effects of mi- cronized fenofibrate in subjects with dyslipidemia [J]. Pol Arch Med Wewn, 2007, 117 (5-6): 235-240. 被引量：1
10Jeanpierre E, Le Tourneau T, Zawadzki C, et al. Beneficial effects of fenofibrate on plaque thrombogenicity and plaque sta- bility in atherosclerotic rabbits [J]. Cardiovasc Pathol, 2009, 18 (3): 140-147. 被引量：1
